Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075504 · ClinicalTrials.gov registry record · Phase 2
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT00075504: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00075504 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075504, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with unresectable or metastatic bile duct or gallbladder cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may help gemcitabine kill more cancer cells by making them more sensitive to the drug.
Interventions
- DRUG gemcitabine
- DRUG triapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075504
The ClinicalTrials.gov registry entry for NCT00075504 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT00075504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075504 about?
NCT00075504 is a clinical study titled "Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer". This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with unresectable or metastatic bile duct or gallbladder cancer. Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop g...
What is the current status of trial NCT00075504?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2003-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00075504?
The interventions under investigation include: gemcitabine (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00075504?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.